Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 242 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: oral intake Clear all

Conditions: Multiple Sclerosis
Interventions: IMU-838 tablets, Placebo matching IMU-838 tablets; Drug
Lead sponsor: Immunic AG; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2033
U.S. locations: 6
States / cities: Phoenix, Arizona • West Hollywood, California • Bradenton, Florida + 3 more

Conditions: Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Interventions: Bocidelpar, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Ovarian Cancer
Interventions: niraparib, everolimus; Drug
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Contraception
Interventions: Norgestrel 0.075 mg; Drug
Lead sponsor: HRA Pharma; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Sacramento, California • Portland, Oregon

Conditions: HR-positive Breast Cancer
Interventions: Vitamin B12, Blood collection, Brief Pain Inventory - Short Form survey, FACT-ES Trial Outcome Index (Version 4), Questionnaire to Assess Adherence to Aromatase Inhibitors, Demographics Questionnaire; Dietary Supplement · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Adult Form of Celiac Disease
Interventions: Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dental Cavity, Caries,Dental
Interventions: Nutritional Counseling; Behavioral
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Solid Tumors
Interventions: Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more

Conditions: Autism Spectrum Disorder
Interventions: STP1, Placebo; Drug
Lead sponsor: Stalicla SA; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Oral Nutrition Supplement; Other
Lead sponsor: Société des Produits Nestlé (SPN); Industry
Eligibility: 20 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Tustin, California

Conditions: Opioid Use Disorder, Sleep Disturbance
Interventions: Post-Illumination Pupillary Response (PIPR), Polysomnography, Multiple Sleep Latency Test, Ecological Momentary Assessments, Actigraphy, DLMO, Melatonin Suppression Test; Other · Behavioral · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Medication Adherence, HIV
Interventions: dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg, tenofovir disoproxil fumarate oral tablet 300mg, lamivudine oral tablet 300mg; Drug
Lead sponsor: Rhonda Brand; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Volunteers
Interventions: [11C]UCB-J, Brivaracetam, Levetiracetam; Radiation · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Gingko Biloba; Dietary Supplement
Lead sponsor: State University of New York College of Optometry; Other
Eligibility: 20 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Venous Leg Ulcers
Interventions: EPA+DHA, placebo; Dietary Supplement · Other
Lead sponsor: Ohio State University; Other
Eligibility: 55 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Refractory Ascites, Hepatic Hydrothorax, Hepatic Encephalopathy, Cirrhosis
Interventions: Oral glutamine challenge, Psychometric Tests; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Osteopenia
Interventions: Calcium Carbonate, Vitamin D3, Risedronate, Bone-loading exercises; Drug · Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Aging, Metabolism
Interventions: Intermittent Fasting, 400 IU Vitamin E, 1000 mg Vitamin C; Other · Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 19 Years to 30 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Prostate Cancer
Interventions: Vitamin D, Omega-3, Turmeric; Dietary Supplement
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Self-Management Support, COPD Education; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 40 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity & Overweight
Interventions: Fuzzle Intraoral Device, Lifestyle Management; Device · Behavioral
Lead sponsor: Fuzzle Operating Co.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Bradenton, Florida

Conditions: Deglutition Disorder
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Advanced Solid Tumors, Lymphoid Malignancies
Interventions: Bardoxolone methyl; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • Cleveland, Ohio • Houston, Texas

Conditions: Endometriosis
Interventions: Vilaprisan (BAY1002670), Matching Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Boynton Beach, Florida • Jacksonville, Florida + 3 more

Search by objective public record fields.

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer

Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients

Effectiveness of a Nutritional Counseling Tool in Reducing the Amount and Frequency of Sugar Intake

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD)

Glycemic Response in Persons With Type 2 Diabetes Mellitus

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

Effects of Ginkgo (Gingko Biloba) on Retinal and Choroidal Ocular Tissue

Impact of Omega-3 Fatty Acid Oral Therapy on Healing of Chronic Venous Leg Ulcers in Older Adults

Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)

Heartland Osteoporosis Prevention Study

Practicality of Intermittent Fasting and Its Effect on Markers of Aging and Oxidative Stress

Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer

Comprehensive Patient-Centered Home-based Care Coaching for COPD Self-management

Fuzzle System for Appetite Control and Weight Management

Effect of Different Viscous Foods and Liquids on Swallowing Sounds

RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies

Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis